All In Biotech

Drug Trial Radar · NCT02446899

Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus

Last checked: Nov 20, 2026Latest source record: Jan 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 373 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

373

Actual

Start

Jul 9, 2015

Primary completion

Sep 27, 2018

Study completion Sep 27, 2018

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
PRA Health Sciences
First posted
May 18, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in adult participants with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).

Conditions

  • Active Systemic Lupus Erythematosus

Interventions

  • AnifrolumabBiological

    Intravenous infusion (IV)

  • PlaceboDrug

    Intravenous infusion (IV)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52Time frame: Baseline; Week 52

Locations

113 sites in 15 countries. Site status is shown where the registry gives one.

  • Research Site

    Covina, California

  • Research Site

    Hemet, California

  • Research Site

    Los Angeles, California

  • Research Site

    San Leandro, California

  • Research Site

    Torrance, California

  • Research Site

    Upland, California

  • Research Site

    Denver, Colorado

  • Research Site

    Bridgeport, Connecticut

  • Research Site

    Bridgeport, Connecticut

  • Research Site

    Brandon, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Palm Harbor, Florida

  • Research Site

    Tamarac, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Boston, Massachusetts

  • Research Site

    Ann Arbor, Michigan

  • Research Site

    Lincoln, Nebraska

  • Research Site

    Las Cruces, New Mexico

  • Research Site

    Brooklyn, New York

  • Research Site

    New York, New York

  • Research Site

    New York, New York

  • Research Site

    New York, New York

  • Research Site

    Greenville, North Carolina

  • Research Site

    Oklahoma City, Oklahoma

  • Research Site

    Duncansville, Pennsylvania

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Memphis, Tennessee

  • Research Site

    Dallas, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Stafford, Texas

  • Research Site

    Arlington, Virginia

  • Research Site

    Seattle, Washington

  • Research Site

    Spokane, Washington

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    Mendoza, Argentina

  • Research Site

    Quilmes, Argentina

  • Research Site

    Brussels, Belgium

  • Research Site

    Leuven, Belgium

Showing 40 of 113 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.